logo-loader
viewParadigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals brings Phase 2 milestone news flow to Spotlight CEO Sessions

Find out more from Paul Rennie at Proactive's CEO Sessions.

no_picture_pai.jpg
Paul Rennie, managing director, Paradigm Biopharmaceuticals​

Paradigm Biopharmaceuticals (ASX:PAR) has key milestone news flow pending.

The company is fully-funded through to the completion of the Phase 2 open label clinical trial for bone bruising, Phase 2 hay fever and Phase 2 alpha viruses trials.

The results have the potential to generate interest from Big Pharma.

Find out more from Paul Rennie at Proactive's CEO Sessions.

Click below to register

- Melbourne: Tuesday 16th May.
- Sydney: Wednesday 17th May.
- Email Pauline here​.
- Call office on (02) 9280 0700.

Presenter list

- Paradigm Biopharmaceuticals (ASX:PAR): CEO Paul Rennie
- Stonewall Resources (ASX:SWJ): MD Robert Thomson
- White Rock Minerals (ASX:WRM): MD Matthew Gill
- The Hydroponics Company (ASX:THC): CEO (medicinal Cannabis division, Canndeo) Andrew Beehag

Final company to be added to the roster

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: 1.69 AUD

ASX:PAR
Market: ASX
Market Cap: $334.31 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: THC Global Group granted GMP Licence for Southport cannabis...

THC Global Group Limited (ASX:THC) chief executive officer Ken Charteris updates Proactive on being granted a licence to manufacture therapeutic goods for the company’s Southport Facility, known as a GMP Licence, by the Australian Therapeutic Goods Administration (TGA). This milestone...

on 01/28/2020

2 min read